PTEN (MMAC1) mutations are frequent in primary glioblastomas (de novo) but not in secondary glioblastomas.
about
Evidence for regulation of the PTEN tumor suppressor by a membrane-localized multi-PDZ domain containing scaffold protein MAGI-2The PEA-15 protein regulates autophagy via activation of JNKMolecular characterizations of glioblastoma, targeted therapy, and clinical results to dateSudden, unexpected death due to glioblastoma: report of three fatal cases and review of the literatureGlioblastoma multiforme: emerging treatments and stratification markers beyond new drugsNeuronatin in a subset of glioblastoma multiforme tumor progenitor cells is associated with increased cell proliferation and shorter patient survivalStructural mutation analysis of PTEN and its genotype-phenotype correlations in endometriosis and cancerAdvances in the genetics of glioblastoma: are we reaching critical mass?Pten regulates homeostasis and inflammation-induced migration of myelocytes in zebrafishClinical significance of EGFR amplification and the aberrant EGFRvIII transcript in conventionally treated astrocytic gliomas.High prevalence of TP53 mutations is associated with poor survival and an EMT signature in gliosarcoma patients.PTEN gene and integrin signaling in cancer.Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity.Phenotype vs genotype in the evolution of astrocytic brain tumors.Current status of viral gene therapy for brain tumours.A novel member of the WD-repeat gene family, WDR11, maps to the 10q26 region and is disrupted by a chromosome translocation in human glioblastoma cells.Epidermal growth factor receptor in glioma: signal transduction, neuropathology, imaging, and radioresistanceThe functional role of Notch signaling in human gliomas.Cancer treatment strategies targeting sphingolipid metabolism.Human papillomavirus-associated subsequent malignancies among long-term survivors of pediatric and young adult cancers.Genetic alterations associated with adult diffuse astrocytic tumors.miR-331-3p regulates expression of neuropilin-2 in glioblastoma.Genetic profile of gliosarcomasGenetic pathways to primary and secondary glioblastomaReceptor protein tyrosine phosphatase zeta as a therapeutic target for glioblastoma therapy.Molecular genetic alterations in radiation-induced astrocytomas.Acquisition of the glioblastoma phenotype during astrocytoma progression is associated with loss of heterozygosity on 10q25-qter.Molecular pathogenesis of pediatric astrocytic tumors.Pediatric high-grade astrocytomas show chromosomal imbalances distinct from adult cases.Sense p16 and antisense uPAR bicistronic construct inhibits angiogenesis and induces glioma cell death.Novel therapeutics in adult malignant brain gliomas.Survival outcomes in glioblastoma multiforme, including the impact of adjuvant chemotherapy.miR-21 Is Linked to Glioma Angiogenesis: A Co-Localization StudyApplications of emerging molecular technologies in glioblastoma multiformeVertebrate animal models of glioma: understanding the mechanisms and developing new therapies.Gliomatosis cerebri: growing evidence for diffuse gliomas with wide invasion.EGFRvIII expression and PTEN loss synergistically induce chromosomal instability and glial tumors.The potential of stem cells for the treatment of brain tumors and globoid cell leukodystrophy.Status of PI3K inhibition and biomarker development in cancer therapeutics.A novel brain tumour model in zebrafish reveals the role of YAP activation in MAPK- and PI3K-induced malignant growth.
P2860
Q22253866-74CB03E1-417F-4E06-A84E-A29C5DC343B5Q24618100-772B635B-26DB-427C-88C4-30DAF83F7822Q26822717-DE67A668-147A-4A44-A116-1AD2D13C794FQ26998556-11BD4C47-2580-475E-89B9-0420EF4415BEQ28082603-E7DEC687-AAFA-4061-A250-940279840D0FQ28729876-FEA35416-F508-4D2B-B047-E9B6D040355CQ30391301-88B35EAB-72CF-4512-A7CD-0D023D1A5EDFQ30426125-3039E51E-D5FA-469E-AC66-C38385657F64Q30577765-0D148E1D-AEB8-4D21-9A85-D8D7AC867FB6Q33628302-22C5E4BD-37BB-4CBE-A19A-0CDCE86302B3Q33646231-5F675B75-49D7-4AD9-8548-0E01014B2A5AQ33765703-DB3B87C8-2331-4909-97BF-D7E6A96370F4Q33774967-24BE219F-4DBC-4C8B-A727-8F901153CD76Q33834813-9A3B331F-238B-48C9-9591-DAB85AE46692Q34074791-DAF2C398-EA58-4631-9A46-27B30928C291Q34089314-AA08B666-DAD3-4990-9E95-65BD1C56833AQ34105339-0FDA6F28-2AB4-464C-9F68-2868B6075668Q34132722-FDDB1823-A633-4AC5-BD28-0EB44A517849Q34790629-C12B9545-7F61-4DBC-A473-FB2022105EFBQ34935007-D40FD33B-DFCB-496E-AC0C-7A9A268F2C66Q34984218-50BBDDAD-05F6-457C-9480-227A90895593Q35021427-6BAC0B27-3941-4E0C-B87C-E3C90D3CC651Q35745419-C79BC8BB-BA0B-4971-BC64-AC25D02BEFACQ35757144-2304D75F-074A-48F4-A1D0-2E0923EDC0AEQ35782888-BA4183CB-C405-4A2C-AD1E-B007A13D3F90Q35786956-F9C99B6D-F5DB-4C7E-A873-2351F509EFE4Q35787692-0B1D6C60-E486-4E03-9F02-A53FFC68E077Q35799973-C8CD031B-1EC9-453D-8D62-9B46A90A0677Q35842014-34A36009-D8E4-47AB-A3EE-B4392E6D9531Q36007325-6EBAE361-0BCC-4AAA-BA5E-D90013CB8175Q36187046-F0558CDF-F0CC-4222-9FF4-45C6CAF3C27AQ36257231-D6F47041-6BA1-4E32-A019-82BCE42F24C2Q36742601-DA9C2507-9AE0-49EB-A649-536340F5AE06Q36965370-E2C58F3E-0CE9-4D58-9B6C-2E10B682CE89Q37058923-18ED8181-A752-4A6C-BE76-34C066D1F0C2Q37139776-7F617BE3-223F-45C2-BA53-5928AB9F70D6Q37284242-8A68570B-5FCE-4157-8AA4-22E8D324FFD9Q37323517-E8349C77-0F6C-4517-9105-E68AC03163CEQ37588308-2F942669-FE7B-4751-9B17-7A7B2A87D51AQ37612660-7198A80E-B5BD-46AD-A86E-957C7CB4AB5D
P2860
PTEN (MMAC1) mutations are frequent in primary glioblastomas (de novo) but not in secondary glioblastomas.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh-hant
name
PTEN (MMAC1) mutations are fre ...... ot in secondary glioblastomas.
@en
type
label
PTEN (MMAC1) mutations are fre ...... ot in secondary glioblastomas.
@en
prefLabel
PTEN (MMAC1) mutations are fre ...... ot in secondary glioblastomas.
@en
P2093
P1476
PTEN (MMAC1) mutations are fre ...... ot in secondary glioblastomas.
@en
P2093
P Kleihues
Y Yonekawa
P304
P356
10.1097/00005072-199807000-00005
P577
1998-07-01T00:00:00Z